title: Pharmacological bridge to cardiac transplantation.
abstract: From September 1985 to August 1988, 32 patients were referred from various intensive care units throughout Paris for urgent cardiac transplantation or for a mechanical bridge to transplantation. At time of admission, under maximal sympathomimetic therapy, the cardiac index (CI) was 1.81 +/- 0.26 l/min per m2, the pulmonary capillary wedge pressure (PCWP 31 +/- 7 mmHg), systemic vascular resistances (SVR) 2053 +/- 469 dynes s cm-5. In 25, diuresis was less than 25 ml/h. Five were anuric. Prior to any final decision, a new inotropic agent, enoximone, was infused in addition to previous treatment as a 10 min bolus iv 1.5-2 mg/kg every 8 h. In 3, the situation further deteriorated, leading to a Jarvik 7-70 implantation within 12 h. In 29 however, within 3 h, the Cl increased to 2.69 +/- 0.56 as SVR dropped to 1410 +/- 453 and PCWP to 18 +/- 7. Diuresis increased to more than 100 ml/h in all. This permitted an indepth evaluation of the transplant candidates leading to contraindications to transplantation in 16. Nine patients could be weaned off iv enoximone. Four of these are still living (NYHA class III) with a follow up of 6-17 months. In 11, transplantation was performed within 2 days. Four died within a month, 2 with multiple organ failure. One patient died after 5 months. Six are back to normal life, NYHA class I (follow up 10 months-2.5 years). This protocol suggests that in patients with extreme heart failure, immediate survival may be increased by iv enoximone therapy, permitting a better selection of the recipients, more efficient pre-transplantation intensive care and consequently a decrease in the indications for a temporary mechanical bridge to a staged transplantation.
authors.affiliation: Department of Cardiac Surgery, C.H.U. Henri Mondor, Créteil, France.
authors.forename: D
authors.initials: D
authors.lastname: Loisance
authors.forename: J L
authors.initials: JL
authors.lastname: Dubois Rande
authors.forename: P H
authors.initials: PH
authors.lastname: Deleuze
authors.forename: M L
authors.initials: ML
authors.lastname: Hillion
authors.forename: A M
authors.initials: AM
authors.lastname: Duval
authors.forename: O
authors.initials: O
authors.lastname: Tavolaro
authors.forename: P
authors.initials: P
authors.lastname: Romano
authors.forename: A
authors.initials: A
authors.lastname: Castaigne
authors.forename: A
authors.initials: A
authors.lastname: Tarral
authors.forename: J P
authors.initials: JP
authors.lastname: Cachera
mesh_terms: D000249:Adenosine Monophosphate / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017335:Enoximone; D005260:Female; D016027:Heart Transplantation; D006354:Heart, Artificial; D006353:Heart-Assist Devices; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D002316:Cardiotonic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D000249:Adenosine Monophosphate; D017335:Enoximone